Fibroblast growth factor receptor 4

Fibroblast growth factor receptor overexpression contributes to the malignant phenotype of a highly aggressive Glioblastoma subgroup and is associated with integrin-related therapeutic vulnerabilities. 1).

Predicts short survival Grade III astrocytoma patients, who require strict adjuvant therapy in accordance with glioblastoma 2).

Higher levels of FGFR-4 in pituitary neuroendocrine tumors could be used as a marker for more aggressive tumor behavior 3).

1)
Gabler L, Jaunecker CN, Katz S, van Schoonhoven S, Englinger B, Pirker C, Mohr T, Vician P, Stojanovic M, Woitzuck V, Laemmerer A, Kirchhofer D, Mayr L, LaFranca M, Erhart F, Grissenberger S, Wenninger-Weinzierl A, Sturtzel C, Kiesel B, Lang A, Marian B, Grasl-Kraupp B, Distel M, Schüler J, Gojo J, Grusch M, Spiegl-Kreinecker S, Donoghue DJ, Lötsch D, Berger W. Fibroblast growth factor receptor 4 promotes glioblastoma progression: a central role of integrin-mediated cell invasiveness. Acta Neuropathol Commun. 2022 Apr 28;10(1):65. doi: 10.1186/s40478-022-01363-2. PMID: 35484633.
2)
Yamada SM, Yamada S, Hayashi Y, Takahashi H, Teramoto A, Matsumoto K. Fibroblast growth factor receptor (FGFR) 4 correlated with the malignancy of human astrocytomas. Neurol Res. 2002 Apr;24(3):244-8. doi: 10.1179/016164102101199864. PMID: 11958417.
3)
Durcan E, Keskin FE, Ozkaya HM, Sirolu S, Sahin S, Korkmaz OP, Gazioglu N, Tanriover N, Comunoglu N, Oz B, Kizilkilic O, Kadioglu P. Fibroblast Growth Factor Receptor-4 Expression in pituitary neuroendocrine tumors is Associated with Aggressive Tumor Features. Exp Clin Endocrinol Diabetes. 2022 Feb;130(2):125-133. doi: 10.1055/a-1523-7216. Epub 2021 Jul 12. PMID: 34255320.